Biogen Inc.(NASDAQ : BIIB)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading BIIB News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.28%||72.67||1.2%||$696.83m|
|REGN||Regeneron Pharmaceuticals, Inc.||-2.85%||358.45||3.6%||$382.78m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.73%||125.07||1.9%||$363.71m|
|VRTX||Vertex Pharmaceuticals Incorporated||-3.11%||75.69||2.9%||$164.83m|
|IONS||Ionis Pharmaceuticals, Inc.||-3.52%||45.78||10.0%||$147.58m|
|BMRN||BioMarin Pharmaceutical Inc.||-1.84%||81.47||4.5%||$114.14m|
|BLUE||Bluebird Bio, Inc.||-9.44%||71.50||23.3%||$112.20m|
|A||Agilent Technologies, Inc.||-0.07%||44.81||1.6%||$111.54m|
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.